Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach

Highlights • Individualized Ramadan-focused advice minimizes risk of hypoglycemic events (HEs). • Patients taking a DPP-4i or gliclazide when fasting during Ramadan have similarly low risks of HEs. • Randomized-controlled studies are needed to assess OADs and incidence of HEs during Ramadan.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes research and clinical practice 2015-08, Vol.109 (2), p.226-232
Hauptverfasser:	Mbanya, Jean Claude, Al-Sifri, Saud, Abdel-Rahim, Aly, Satman, Ilhan
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - drug effects Diabetes Diabetes Mellitus, Type 2 - blood Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - psychology Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Endocrinology & Metabolism Fasting Gliclazide Gliclazide - adverse effects Gliclazide - therapeutic use Humans Hypoglycemia - blood Hypoglycemia - chemically induced Hypoglycemia - epidemiology Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Incidence Islam Ramadan
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Individualized Ramadan-focused advice minimizes risk of hypoglycemic events (HEs). • Patients taking a DPP-4i or gliclazide when fasting during Ramadan have similarly low risks of HEs. • Randomized-controlled studies are needed to assess OADs and incidence of HEs during Ramadan.
ISSN:	0168-8227 1872-8227 1872-8227
DOI:	10.1016/j.diabres.2015.04.030